ENTRADA THERAPEUTICS INC (TRDA) Stock Earnings & Estimates
USA - NASDAQ:TRDA - US29384C1080 - Common Stock
5.28 USD
-0.14 (-2.58%)
5.28 USD
0 (0%)
Full estimates are only available for subscribed users, you can see which data is available below.
Subscribed users also see more surprise data, now it is restricted to 4 quarters.
Examples of complete estimate data are available for MSFT and AAPL.
Registered users have access to more data. Please register or login for additional estimates and surprises .
| 2022 | 2023 | 2024 | 2025 | 2026 | 2027 | 2028 | 2029 | 2030 | ||
|---|---|---|---|---|---|---|---|---|---|---|
| Revenue YoY % growth | 129.013M | 210.782M 63.38% | 34.741M -83.52% | 25.813M -25.70% | 57.548M 122.94% | -100.00% | 25.5M | |||
| EBITDA YoY % growth | -95.35M -90.66% | -321K 99.66% | 50.784M 15,920.56% | -137.757M -371.26% | -153.572M -11.48% | -149.16M 2.87% | N/A | N/A | N/A | |
| EBIT YoY % growth | -97.25M -90.20% | -3.162M 96.75% | 47.011M 1,586.75% | -163.037M -446.81% | -217.614M -33.48% | -219.421M -0.83% | -255M -16.22% | -280.5M -10.00% | -288.15M -2.73% | |
| Operating Margin | N/A | -2.45% | 22.30% | -469.29% | -843.04% | -381.28% | N/A | N/A | -1,130.00% | |
| EPS YoY % growth | -3.02 63.24% | -0.26 91.39% | 1.91 834.62% | -3.60 -288.51% | -4.65 -29.18% | -4.25 8.66% | 6.18 245.50% | N/A | N/A |
All data in USD
| Q3 / 25 | Q4 / 25 | Q1 / 26 | Q2 / 26 | Q3 / 26 | Q4 / 26 | |
|---|---|---|---|---|---|---|
| EPS Q2Q % growth | -1.01 -189.24% | -1.09 -3,738.00% | -1.08 -157.43% | -1.13 -8.37% | -1.16 -14.83% | -1.24 -14.02% |
| Revenue Q2Q % growth | 9.216M -52.91% | 6.156M -83.54% | 9.489M -53.84% | 4.796M 145.95% | 8.196M -11.07% | 8.196M 33.14% |
| EBITDA Q2Q % growth | N/A | N/A | N/A | N/A | N/A | N/A |
| EBIT Q2Q % growth | -44.105M -103.64% | -48.956M -734.42% | -61.307M -181.35% | -64.606M -37.90% | -68.091M -54.38% | -71.773M -46.61% |
All data in USD
| Period | Reported | Estimate | Difference | Surprise |
|---|---|---|---|---|
| Q2 2025 Q2Q % growth | -1.04 -167.10% | -0.86 | -0.18 | -20.31% |
| Q1 2025 Q2Q % growth | -0.42 -161.76% | -0.80 | 0.38 | 47.81% |
| Q4 2024 Q2Q % growth | 0.03 110.34% | -0.68 | 0.71 | 104.39% |
| Q3 2024 Q2Q % growth | -0.35 -134.31% | -0.74 | 0.39 | 52.87% |
| Q2 2024 Q2Q % growth | 1.55 298.72% | 0.15 | 1.40 | 948.01% |
| Q1 2024 Q2Q % growth | 0.68 423.81% | -0.61 | 1.29 | 212.23% |
| Q4 2023 Q2Q % growth | -0.29 63.29% | -0.17 | -0.12 | -69.23% |
| Q3 2023 Q2Q % growth | 1.02 227.50% | -0.75 | 1.77 | 235.92% |
| Q2 2023 Q2Q % growth | -0.78 -5.41% | -0.70 | -0.08 | -10.83% |
| Q1 2023 Q2Q % growth | -0.21 69.57% | 0.99 | -1.20 | -121.28% |
| Q4 2022 Q2Q % growth | -0.79 11.24% | -0.84 | 0.05 | 6.31% |
| Q3 2022 Q2Q % growth | -0.80 91.82% | -0.78 | -0.02 | -3.20% |
| Q2 2022 Q2Q % growth | -0.74 | -0.74 | 0.00 | -0.21% |
| Q1 2022 Q2Q % growth | -0.69 | -0.67 | -0.02 | -3.28% |
| Q4 2021 Q2Q % growth | -0.89 | -1.31 | 0.42 | 32.04% |
| Q3 2021 Q2Q % growth | -9.78 | -0.89 | -8.89 | -1,002.10% |
| Period | Reported | Estimate | Difference | Surprise |
|---|---|---|---|---|
| Q2 2025 Q2Q % growth | 1.95M -97.94% | 9.844M | -7.894M | -80.19% |
| Q1 2025 Q2Q % growth | 20.558M -65.23% | 10.374M | 10.184M | 98.17% |
| Q4 2024 Q2Q % growth | 37.398M -10.63% | 13.383M | 24.015M | 179.44% |
| Q3 2024 Q2Q % growth | 19.57M -55.25% | 12.567M | 7.003M | 55.73% |
| Q2 2024 Q2Q % growth | 94.694M 421.16% | 46.997M | 47.697M | 101.49% |
| Q1 2024 Q2Q % growth | 59.12M 134.05% | 15.276M | 43.844M | 287.01% |
| Q4 2023 Q2Q % growth | 41.848M | 24.169M | 17.679M | 73.15% |
| Q3 2023 Q2Q % growth | 43.735M | 9.789M | 33.946M | 346.78% |
| Q2 2023 Q2Q % growth | 18.17M | 9.972M | 8.198M | 82.21% |
| Q1 2023 Q2Q % growth | 25.26M | 121.38M | -96.12M | -79.19% |
| Next Q (1 month) | Next Q (3 month) | Next Year (1 month) | Next Year (3 month) | |
|---|---|---|---|---|
| EPS | 0% | -9.97% | 0% | -9.09% |
| Revenue | 5.97% | -3.89% | -11.7% | -21.26% |